Aster Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Aster Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-155	Closed	-$6.39K	–	1106
2025 Q4	$6.39K	Buy	+155	New	+$6.22K	﹤0.01%	831
2025 Q3	–	Sell	-21,398	Closed	-$592K	–	1181
2025 Q2	$592K	Buy	21,398 +19,942	+1,370%	+$508K	0.13%	182
2025 Q1	$29.5K	Buy	+1,456	New	+$30K	0.01%	923

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Aster Capital Management's KNSA Position: Q1 2026 in Review

Aster Capital Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 155 shares — an estimated $6.39K sold.

Aster Capital Management first reported a position in KNSA in Q1 2025 and held it in 3 quarters. The position peaked at $592K in Q2 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Aster Capital Management reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Aster Capital Management sold 155 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $6.39K.
Aster Capital Management first reported a position in Kiniksa Pharmaceuticals in Q1 2025 and held it in 3 quarters.
Aster Capital Management's Kiniksa Pharmaceuticals position peaked at $592K in Q2 2025.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.